(NASDAQ: SNDX) Syndax Pharmaceuticals's forecast annual revenue growth rate of 59.03% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Syndax Pharmaceuticals's revenue in 2026 is $172,352,000.On average, 16 Wall Street analysts forecast SNDX's revenue for 2026 to be $32,234,671,820, with the lowest SNDX revenue forecast at $20,053,287,507, and the highest SNDX revenue forecast at $41,943,793,428. On average, 15 Wall Street analysts forecast SNDX's revenue for 2027 to be $48,752,879,439, with the lowest SNDX revenue forecast at $25,844,538,640, and the highest SNDX revenue forecast at $84,275,669,478.
In 2028, SNDX is forecast to generate $60,090,184,049 in revenue, with the lowest revenue forecast at $31,722,226,357 and the highest revenue forecast at $81,591,725,342.